Key Findings from the PECATI Trial at ESMO 2024

The results of the PECATI trial were recently presented at ESMO 2024.

The PECATI trial is a single-arm, investigator-initiated Phase II study designed to evaluate the activity and safety of combining lenvatinib and pembrolizumab in 43 patients with advanced B3-thymoma or thymic carcinoma who have progressed after at least one line of platinum-based chemotherapy.

The primary endpoint is the 5-month progression-free survival rate, while secondary endpoints include overall response rate, duration of response, and overall survival.

The principal investigator (PI) for the PECATI trial is Jordi Remon

The results of the PECATI trial were recently presented at ESMO24.

Doctors shared their insights on social media:

Antonio Calles:

“Important to promote academic trials in rare thoracic conditions.

Jordi Remon presents data on PECATI trial: Lenvatinib and Pembrolizumab in metastatic B3-thymoma or thymic carcinoma.

5-months PFS rate, 88%, dose efficacy relationship, and ocasional challenging tox.”

Benjamin Besse:

“ Impressive benefit for Lenvatinib–Pembrolizumab in patients with thymic carcinoma and B3 thymoma.

ORR 23.3% and mPFS 14.9m are unexpected in 2nd line or more. Lenvatinib dose matters in a subgroup analysis. Congratulations Jordi Remon.”

Sanjay Popat:

“Fiona Blackhall discusses PECATI compares to CAVEATT (avel+axitinib).

Reminds us PDL1 is thymic epithelium marker and not IO sensitivity as shown in both PECATI and CAVEATT.

Agrees with Jordi Remon’s conclusions summarizes EU can run thymic trials. We need randomized data.”

Joshua Reuss:

“ Fiona Blackhall places PECATI Study in context of challenges of trial design and therapeutic landscape of B3 thymoma and thymic malignancies at ESMO24.”

Noemi Reguart:

“ Jordi Remon elegantly presenting PECATI phase 2 lenvatinib plus pembro in pretreated B3-thymoma and thymic carcinoma. Primary endpoint met 5-mo PFS 88%. Promising 12-mo OS 85%. Higher dose intensity associated with better outcomes. Manageable safety BUT irAE 14%.”

Jordi Remon:

“Thymic Epithelial Tumors remain a rare and orphan disease. Results of PECATI trial may help to increase patient outcomes with metastatic B3Thymoma and Thymic Carcinoma.

Multidisciplinary approach is also crucial for these rare tumours.”

PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients

Authors: Jordi Remon, Nicolas Girard, Silvia Novello, Javier de Castro, Laurence Bigay-Game, Reyes Bernabé, Laurent Greillier, Joaquin Mosquera, Sophie Cousin, Oscar Juan, Miguel Sampayo, and Benjamin Besse.

For more updates on ESMO24, visit oncodaily.com.